Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)

被引：0
作者：
Iliana Doycheva
Rohit Loomba
机构：
[1] University of California,Division of Gastroenterology, Department of Medicine
[2] San Diego,Division of Epidemiology, Department of Family and Preventive Medicine
[3] University of California,undefined
[4] San Diego,undefined
来源：
Advances in Therapy | 2014年 / 31卷
关键词：
Body mass index; Hepatocellular ballooning; Liver histology; Metformin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The key histologic feature of nonalcoholic steatohepatitis (NASH) is hepatocellular ballooning (HB). It plays an important role in NASH progression and is an independent predictor of liver mortality. In this review, we identified all studies using metformin in the treatment of nonalcoholic fatty liver disease (NAFLD) that included pre- and post-treatment liver biopsies. We specifically reviewed the effects of metformin on HB. Improved HB was noted in pediatric populations and in those adult patients who were able to lose weight and improve or normalize transaminases during therapy. Previous studies have supported the beneficial effects of metformin in reduction of body weight, improvement of insulin resistance, prevention of complications related to diabetes and chemo-preventive benefits in reducing hepatocellular carcinoma. All these effects make it an attractive treatment consideration for patients with diabetes, and prediabetes who have co-existing NAFLD. Future studies are warranted in order to confirm this effect of metformin on HB and its association with improving long-term outcomes in patients with NAFLD.
引用
收藏
页码：30 / 43
页数：13
相关论文
共 184 条
[1]  
Bellentani S(2010)Epidemiology of non-alcoholic fatty liver disease Dig Dis 28 155-161
[2]  
Scaglioni F(2011)Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 124-131
[3]  
Marino M(2009)Advances in pediatric nonalcoholic fatty liver disease Hepatology 50 1282-1293
[4]  
Bedogni G(2005)Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 1313-1321
[5]  
Williams CD(2010)Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection Hepatology 51 1820-1832
[6]  
Stengel J(2011)Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective Expert Rev Gastroenterol Hepatol 5 223-231
[7]  
Asike MI(2012)Costaining for keratin 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease Hum Pathol 43 790-800
[8]  
Loomba R(2010)Hepatocellular ballooning in NASH J Hepatol 53 719-723
[9]  
Sirlin CB(1999)Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1413-1419
[10]  
Schwimmer JB(2004)Pathologic features associated with fibrosis in nonalcoholic fatty liver disease Hum Pathol 35 196-199
12345678910